Articles related to SIDE EFFECTS

Physical symptoms following antidepressant cessation are generally transient and consistent with established discontinuation phenomena, while persistent or delayed symptoms remain difficult to explain pharmacodynamically and may involve psychiatric, psychological, or somatic contributors.

Two phase 3 trials found upadacitinib increased scalp, eyebrow, and eyelash regrowth in adolescents and adults with severe alopecia areata. Longer-term safety, durability, and regulatory review remain important considerations.

New consensus guidance favors once-daily oral iron and simplified IV administration, including fewer test doses, premedications, and infusion visits. Several recommendations depart from established protocols and require formulation-specific clinical judgment.

Daily low-dose endoxifen reduced mammographic breast density versus placebo in premenopausal women, with fewer tolerability concerns at 1 mg. Whether this surrogate response translates into lower breast cancer incidence remains unknown.

Rodent and non-human primate studies showed glucagon and GIP agonism alone produced weight loss comparable to GLP-1-containing triple agonists in a Bluewater Biosciences-funded program.

Eleven commonly prescribed medication classes have been associated with new or worsening depression symptoms, with risk varying by dose, duration, and patient population.